Cover Image

Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Yanxue Lin, Xueping Yu, Huimin Lin, Jiajia Han, Yan Yan, Xiaoting Zhao, Yijie Lin, Zixuan Huang, Yinyin Zheng, Yahong Gao, Wenjin Yuan, Meifang Zhou, Jiming Zhang, Dawu Zeng
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical Trial: Hepatitis B Virus Genotype and a Combination of End‐of‐Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation
by: Arno Furquim d’Almeida, et al.
Published: (2025)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’
by: Dong Hyun Kim, et al.
Published: (2025)

Letter on “Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China”
by: Ersel Bilgin, et al.
Published: (2025)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’—Authors' Reply
by: Ning Yu, et al.
Published: (2025)

Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono‐Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study
by: Raffaella Viganò, et al.
Published: (2025)

Editorial: A Step Back to Leap Forward—Strategic Nucleos(t)ide Analogue Discontinuation Towards HBV Functional Cure
by: Xuwen Xu, et al.
Published: (2025)

Letter: Dynamic HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation: Considerations in Interpreting Predictive Performance
by: Hsiang‐Ting Keng, et al.
Published: (2026)

Editorial: Using HBcrAg and HBsAg Kinetics to Optimise Monitoring After Nucleo(s)tide Analogue Withdrawal
by: Edo J. Dongelmans, et al.
Published: (2026)

Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss
by: Ying‐Nan Tsai, et al.
Published: (2026)

Editorial: Using HBcrAg and HBsAg Kinetics to Optimise Monitoring After Nucleo(s)tide Analogue Withdrawal. Authors' Reply
by: Yasuhito Tanaka, et al.
Published: (2026)

Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10‐Year French Nationwide Cohort Study
by: Laurent Lam, et al.
Published: (2024)

Editorial on ‘Early HBcrAg and Anti‐ HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation: A Pooled Analysis of Two Clinical Trials’
by: Ming Chao Tsai, et al.
Published: (2025)

Systematic Review: Incidence of Liver‐Related Events in People Living With Hepatitis Delta Virus
by: Laura E. Telep, et al.
Published: (2025)

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma
by: Jia‐Ling Wu, et al.
Published: (2025)

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia
by: Paul Y. Kwo, et al.
Published: (2026)

Surviving Hepatitis C—Understanding Death and Survival Beyond Cure
by: Paul J. Clark, et al.
Published: (2025)

Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues
by: Tyng‐Yuan Jang, et al.
Published: (2025)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
by: Yi‐Ping Hung, et al.
Published: (2024)

Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
by: Yu‐Ping Chang, et al.
Published: (2025)

Editorial: Hepatitis C virus eradication improves skeletal muscle mass
by: Catherine Jia Lin Tian, et al.
Published: (2024)

Editorial: HBV Integration—A Possible Key Driver on the Course of Patients With Chronic HBV Infection Under Viral Suppression. Authors' Reply
by: Qin Ning, et al.
Published: (2025)

Review Article: Drug‐Induced Liver Injury Associated With Antibody‐Based Therapies in Haematologic Malignancies
by: Mengmeng Lin, et al.
Published: (2025)

Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
by: Juan Macias, et al.
Published: (2024)

Burden of Invasive Fungal Diseases in Patients With Alcohol‐Related Hepatitis and Organ Failure
by: Charlotte Mouliade, et al.
Published: (2025)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
by: Pei‐Chien Tsai, et al.
Published: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
by: Rong‐Xiang Ng, et al.
Published: (2025)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
by: Yu Shi, et al.
Published: (2025)

Editorial: Hepatitis D Screening—DAS (Delta Virus Awareness and Screening) Approach in Primary Care
by: Noreen Singh, et al.
Published: (2025)

Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
by: Yu‐Sheng Lin, et al.
Published: (2026)

Favourable Prognosis of Patients With Untreated HBeAg‐Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU/mL
by: Jian Wang, et al.
Published: (2024)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
by: Juan Macias, et al.
Published: (2025)

Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐On‐Chronic Liver Failure
by: Amy Sangam, et al.
Published: (2024)

Letter: Methodological Considerations in Comparing Liver Outcomes of Glucagon‐Like Peptide‐1 Receptor and Sodium Glucose Cotransporter‐2 Inhibitors
by: Cheng‐Hsien Hung, et al.
Published: (2025)

Clinical Trial: Immunogenicity of Double‐Dose Versus Standard‐Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease
by: Anupam Kumar Singh, et al.
Published: (2025)

Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death
by: Mathias Jachs, et al.
Published: (2025)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
by: Luis Calzadilla Bertot, et al.
Published: (2025)

Robust Predictive Performance of the SALT‐M Score for Clinical Outcomes in Asian Patients With Acute‐on‐Chronic Liver Failure
by: Kunhee Kim, et al.
Published: (2024)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
by: Nobuharu Tamaki, et al.
Published: (2025)

Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment
by: Shiva Poola, et al.
Published: (2025)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
by: Terry Cheuk‐Fung Yip, et al.
Published: (2025)